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1950–2007) and from the WHO (years 1997–2006). Global
person-year exposure to bromocriptine was estimated using data
from IMS. Next, we conducted a retrospective matched cohort
study using data from the GPRD (years 1990–2006). Age- and
multivariate-adjusted Cox proportional hazard models were con-
structed to calculate a hazard ratio (HR) and 95% conﬁdence
interval (CI) of CVD events among bromocriptine users com-
pared to controls. RESULTS: We identiﬁed 24 CVD events pub-
lished in the worldwide medical literature and 56 CVD events
reported to the WHO over an estimated 19.3 million person-
years of bromocriptine exposure. At least 92% of reported CVD
events were among women in either data set. In our GPRD
cohort, 88% of patients exposed to bromocriptine for any
speciﬁed indication were women. After multivariate adjustment,
patients exposed to bromocriptine appeared to have lower risk of
a CVD event, although not statistically signiﬁcant, HR 0.82
(95% CI 0.29 to 2.31). Gender was not a signiﬁcant confounder
in the multivariate model. CONCLUSION: Using public report-
ing systems, CVD events appear to occur infrequently among
patients taking bromocriptine but predominately among women.
Results from our GPRD analysis are not consistent with an
increased risk of CVD events among patients taking bromocrip-
tine; rather, they suggest a decreased risk. These ﬁndings high-
light the need for careful epidemiologic study to consider the
potential risks associated with bromocriptine speciﬁcally and
medications in general.
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OBJECTIVE: Evaluate cardiovascular disease (CVD) outcomes
in managed care patients upon adherence to lipid treatment
guidelines [National Cholesterol Education Program’s Third
Report on Detection, Evaluation, and Treatment of High Blood
Cholesterol and Adult Treatment Panel’s (NCEP-ATP III)].
METHODS: Patients with laboratory values for low-density
lipoprotein-cholesterol (LDL-C), high-density lipoprotein-
cholesterol (HDL-C), & triglycerides (TG) between January 1,
2003-December 31, 2005 [index date], no lipid therapy
6-months pre-index date, and minimum 12 months health plan
eligibility pre- and post-index date were analyzed using the
HealthCore integrated managed care database. Patients were
classiﬁed as appropriately (AM) or inappropriately managed
(IAM) using baseline lipid levels and the ﬁrst post-index
follow-up lipid panel (goal attainment), and risk stratiﬁcation per
NCEP-ATP III guidelines. Impacts on lipid parameters between
groups were descriptively analyzed, while multivariate logistic
regression was performed to estimate risk of CVD events
(ischemic heart disease, peripheral vascular disease, stroke and
related occurrences and interventions). RESULTS: Among 8176
study patients (3493 AM; 4683 IAM), AM patients were signiﬁ-
cantly older [51.4  9.1 and 50.0  9.6 years, p < 0.01] and
comprised of fewer males (43.2% vs. 56.2%; p < 0.01). Mean
LDL-C, HDL-C, and TG baseline levels were signiﬁcantly differ-
ent among AM patients (127  35, 55  15, and 131  66 vs.
132  37, 45  13, and 181  81 respectively; p < 0.01).
During follow-up, AM patients had greater decreases in LDL-C
and TG levels versus IAM patients (-12% vs. –3% and –8% vs.
+5%; p < 0.01), while HDL-C levels showed greater increases
(5% vs. 2%; p < 0.01). AM patients were 38% less likely
to experience a CVD event versus IAM patients [Odds
Ratio = 0.62; 95% CI, 0.48–0.80; p < 0.01]. CONCLUSION:
Greater improvement in all three lipid parameters and reduction
in CVD event risk occurred among dyslipidemia patients
managed in accordance with clinical guideline treatment recom-
mendations in this managed care population.
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OBJECTIVE: To assess the budget impact of reimbursing
aliskiren (Tekturna/Rasilez), the ﬁrst drug from a new class of
antihypertensive drugs (direct renin inhibitors), for the man-
agement of essential hypertension, from the health care payer
(RIZIV/INAMI), patient, and societal perspectives in Belgium.
METHODS: Following ISPOR’s budget impact guidelines, the
pharmacy costs of the current therapy distribution of patients
treated for essential hypertension in Belgium was compared to an
alternative scenario, where aliskiren gains market share from
conventional ARB therapy over a 3-year time horizon. IMS data-
bases and literature data were used to estimate the total number
of treated hypertensive patients and to derive market shares of
the different antihypertensive medication classes (Beta-blocker,
CCB, Diuretic, ACEi, ARB) and all possible dual and triple
combinations thereof. The antihypertensive market share uptake
of aliskiren was assumed to be identical to that observed previ-
ously for telmisartan in Belgium (0.16% year 1; 0.24% year 2;
and 0.28% year 3). Only drug acquisition costs (obtained from
ofﬁcial Tariffs) were considered in this analysis. Univariate sen-
sitivity analyses were performed as well as sub-populations
analyses. RESULTS: The predicted Belgian populations treated
for hypertension in 2008, 2009, and 2010 were estimated at
1,398,446 patients; 1,426,137 patients; and 1,525,827 patients,
respectively. Over 3 years, it was estimated that RIZIV/INAMI
hypertension drug budget following aliskiren reimbursement
would increase by 0.02% (i.e. €148,395), from €755,522,606 to
€755,671,001. Patients’ co-payments would decrease by
€20,613, resulting in societal incremental costs of €127,782.
Sensitivity analyses conﬁrmed that the net budget impact would
remain of the same magnitude. CONCLUSION: Our analyses
suggest that, under current assumptions, reimbursing aliskiren in
Belgium would only slightly increase costs from the RIZIV/
INAMI and societal perspectives, while generating savings for
patients. Moreover, this budget impact does not consider
aliskiren potential savings due to end organ protection.
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OBJECTIVE: Heart failure (HF) is a major public health burden
in terms of mortality, morbidity and costs. Economic analyses of
clinical trials and real-world studies have assessed the cost-
effectiveness of drugs used to treat HF. Although a few papers
have summarized the results of the earlier economic studies, new
evidence has emerged necessitating an update of the cost-
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